Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jun;74(6):1325-1334.
doi: 10.1016/j.jhep.2020.12.033. Epub 2021 Jan 24.

Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score

Affiliations
Multicenter Study

Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score

Eleonora De Martin et al. J Hepatol. 2021 Jun.

Abstract

Background & aims: In acute severe autoimmune hepatitis (AS-AIH), the optimal timing for liver transplantation (LT) remains controversial. The objectives of this study were to determine early predictive factors for a non-response to corticosteroids and to propose a score to identify patients in whom LT is urgently indicated.

Methods: This was a retrospective, multicenter study (2009-2016). A diagnosis of AS-AIH was based on: i) Definite or probable AIH based on the simplified IAIHG score; ii) international normalized ratio (INR) ≥1.5 and/or bilirubin >200 μmol/L; iii) No previous history of AIH; iv) Histologically proven AIH. A treatment response was defined as LT-free survival at 90 days. The evolution of variables from corticosteroid initiation (day-D0) to D3 was estimated from: Δ%3 = (D3-D0)/D0.

Results: A total of 128 patients were included, with a median age of 52 (39-62) years; 72% were female. Overall survival reached 88%. One hundred and fifteen (90%) patients received corticosteroids, with a LT-free survival rate of 66% at 90 days. Under multivariate analysis, D0-INR (odds ratio [OR] 6.85; 95% CI 2.23-21.06; p <0.001), Δ%3-INR ≥0.1% (OR 6.97; 95% CI 1.59-30.46; p <0.01) and Δ%3-bilirubin ≥-8% (OR 5.14; 95% CI 1.09-24.28; p <0.04) were predictive of a non-response. The SURFASA score: -6.80+1.92∗(D0-INR)+1.94∗(Δ%3-INR)+1.64∗(Δ%3-bilirubin), created by combining these variables, was highly predictive of LT or death (AUC = 0.93) (88% specificity; 84% sensitivity) with a cut-off point of <-0.9. Below this cut-off, the chance of responding was 75%. With a score higher than 1.75, the risk of dying or being transplanted was between 85% and 100%.

Conclusion: In patients with AS-AIH, INR at the introduction of corticosteroids and the evolution of INR and bilirubin are predictive of LT or death. Within 3 days of initiating corticosteroids, the SURFASA score can identify non-responders who require a referral for LT. This score needs to be validated in a prospective cohort.

Lay summary: The management of patients with acute severe autoimmune hepatitis is highly challenging, particularly regarding their early referral for liver transplantation. We found that international normalized ratio at the initiation of corticosteroid therapy and the evolution of international normalized ratio and bilirubin values after 3 days of therapy were highly predictive of liver transplantation or death. We are thus proposing a score that combines these variables and identifies patients in whom liver transplantation is urgently required.

Keywords: autoimmune hepatitis; corticosteroid therapy; liver transplantation; prognostic score; severe acute hepatitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest EDM: nothing to disclose, AC: nothing to disclose, OC: nothing to disclose, OR: nothing to disclose, JMP: nothing to disclose, PHD: nothing to disclose, FA: nothing to disclose, CS: nothing to disclose, IOH: nothing to disclose, CD: nothing to disclose, AHB: nothing to disclose, SB: nothing to disclose, NG: nothing to disclose, GPP: nothing to disclose, CB: nothing to disclose, MB: nothing to disclose, HF: nothing to disclose, VdL: nothing to disclose, JD: nothing to disclose, FC: nothing to disclose, SR: nothing to disclose, MDG: nothing to disclose, OG: nothing to disclose, FD: nothing to disclose, PP: nothing to disclose, VDM: nothing to disclose, NR: nothing to disclose, PI: nothing to disclose, MS: nothing to disclose, PM: nothing to disclose, HA: nothing to disclose, DS: nothing to disclose, JCDV: nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment in

Publication types

MeSH terms